Related Experiment Video
Updated: Feb 11, 2026

Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology
Published on: December 15, 2017
Generic Price Competition For Specialty Drugs: Too Little, Too Late?
Ashley L Cole1, Stacie B Dusetzina2
1Ashley L. Cole is a doctoral candidate in the Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, and a predoctoral fellow at the Cecil G. Sheps Center for Health Services Research, both at the University of North Carolina at Chapel Hill.
Abstract:
The case of generic imatinib demonstrates several potential barriers to effective generic price competition for specialty prescription drugs, including fewer market entrants, smaller-than-expected price reductions, shifts in prescribing toward more expensive brand-name treatments, and limited uptake of the generic product.
Related Concept Videos
Competition
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Although all competitive neuromuscular blockers are designed...
Pharmacokinetics: Drug–Drug Interactions

